Comparative Pharmacology
Head-to-head clinical analysis: AUKELSO versus LOTRIMIN AF.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AUKELSO versus LOTRIMIN AF.
AUKELSO vs LOTRIMIN AF
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective inhibitor of the mammalian target of rapamycin (mTOR) kinase, specifically the mTORC1 complex, leading to inhibition of cell proliferation, angiogenesis, and glucose uptake.
Inhibits fungal cytochrome P450 14α-demethylase, blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
400 mg orally twice daily with food.
Topical: Apply twice daily (morning and evening) to affected area for 2-4 weeks. Intravaginal: One 200 mg suppository vaginally at bedtime for 3 days, or one 500 mg vaginal tablet as a single dose.
None Documented
None Documented
Terminal elimination half-life approximately 24 hours (range 20–28 h), supports once-daily dosing; prolonged in severe hepatic impairment.
Terminal elimination half-life of absorbed clotrimazole is approximately 3.5–4 hours, but this is clinically irrelevant due to negligible systemic absorption after topical application.
Primarily hepatic metabolism with biliary excretion; ~20% renal elimination of unchanged drug. Fecal excretion of metabolites accounts for ~65% of total clearance.
Less than 1% of topical clotrimazole is absorbed; absorbed drug is metabolized in the liver to inactive metabolites and excreted primarily in feces (approximately 69%) and urine (approximately 21%) via biliary and renal routes.
Category C
Category C
Topical Antifungal
Topical Antifungal